Evidence map›Paper›PMID 36819160›Full record

ArticleEJHaem2023

Global longitudinal strain is superior to ejection fraction for long-term follow-up after allogeneic hematopoietic stem cell transplantation.

Marika Watanabe, Kimikazu Yakushijin, Hidekazu Tanaka, Ruri Chijiki, Miki Saeki, Yuri Hirakawa, Hidetomo Takakura, Yutaro Usui, Hiroya Ichikawa, Rina Sakai and 12 more

Open access · diamondAbstract read
In one paragraph

Article in EJHaem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 2 countries.

Marika WatanabeDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.ORCID https://orcid.org/0000-0002-8874-8093
Kimikazu YakushijinDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.ORCID https://orcid.org/0000-0003-2511-7857
Hidekazu TanakaDivision of Cardiovascular Medicine Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.
Ruri ChijikiDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Miki SaekiDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Yuri HirakawaDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Hidetomo TakakuraDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Yutaro UsuiDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Hiroya IchikawaDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Rina SakaiDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Sakuya MatsumotoDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Shigeki NagaoDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Yu MizutaniDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Keiji KurataJerome Lipper Multiple Myeloma Center Department of Medical Oncology Dana-Farber Cancer Institute Harvard Medical School Boston Massachusetts USA.
Akihito KitaoDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Yoshiharu MiyataDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Yasuyuki SaitoDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Shinichiro KawamotoDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Katsuya YamamotoDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Mitsuhiro ItoDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Hiroshi MatsuokaDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.ORCID https://orcid.org/0000-0003-4443-4372
Hironobu MinamiDivision of Medical Oncology and Hematology Department of Medicine Kobe University Hospital Kobe Japan.
Kobe University Hospital · JPHarvard University · USKobe University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Global longitudinal strain (GLS), a new cardiac parameter measured by the speckle-tracking method, is reportedly more sensitive than ejection fraction (EF) in detecting slight cardiac dysfunction in heart failure patients. We validated the utility of GLS in allogeneic hematopoietic stem cell transplantation (HSCT) patients during a long-term follow-up. Medical records of patients who underwent allogeneic HSCT between 2013 and 2020 were reviewed retrospectively. We evaluated the last echocardiography performed before transplantation and those performed annually during the 5 years after transplantation. We also investigated newly diagnosed cardiac events, which developed after HSCT. Among 85 patients, 22 used cardioprotective drugs. The median follow-up duration in surviving patients was 54.1 months (range, 2.9-92.6 months). GLS significantly decreased year by year, and patients taking cardioprotective agents tended to have a better GLS at 5 years than at 3 years, while EF did not change. Fifteen patients developed newly diagnosed cardiac events. Multivariate analysis revealed that low GLS and high serum ferritin levels at baseline were independently associated with the development of cardiac events. Therefore, we need a continuous follow-up of cardiac function by GLS and prescription of cardioprotective drugs might be considered for HSCT patients with low GLS. Further research is warranted.

Indexed as

cardiac diseaseglobal longitudinal strainhematopoietic stem cell transplantationposttransplant complication

Identifiers

PMID36819160
PMCPMC9928647
OpenAlexW4308410962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.